Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Metastatic HR+/HER2- Breast Cancer Market From 2025 To 2029?
The market size for metastatic hr+/her2- breast cancer has seen rampant expansion in recent years. The growth is expected to surge from $9.91 billion in 2024, reaching $10.89 billion in 2025 with a compound annual growth rate (CAGR) of 10.0%. Factors contributing to the historical growth include heightened awareness regarding early detection, increased rates of diagnosis, successes in clinical trials, investments in pharmaceuticals, and the increasing preference for combination therapies.
The market size for metastatic hr+/her2- breast cancer is anticipated to witness a significant rise in the upcoming years, surging to$15.79 billion in 2029 with a compound annual growth rate (CAGR) of 9.7%. Factors contributing to this growth within the forecast period include the widespread acceptance of groundbreaking treatments, increased usage of immunotherapy, expansion into developing markets, patient advocacy and aid programs, as well as an emphasis on enhancing quality of life. The forecast period is also expected to see major trends such as next-gen sequencing (NGS), advancement in liquid biopsy, the discovery of biomarkers, cell and gene therapy, and monoclonal antibodies (mAbs).
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21220&type=smp
What are the Fundamental Drivers and Innovations Shaping the Metastatic HR+/HER2- Breast Cancer Market?
The surge in hormone replacement therapy (HRT) is anticipated to spur the growth of the metastatic HR+/HER2− breast cancer market. HRT is a medical intervention that supplements or replaces hormones that are deficient in the body, often during menopause or hormone deficiencies. The rise in hormone replacement therapy (HRT) is due to its efficiency in enhancing treatment outcomes, and its lesser side effects compared to traditional therapies, and developments in precision medicine. HRT bolsters the fight against metastatic HR+/HER2− breast cancer by relieving estrogen deficiency symptoms related to menopause, such as hot flashes and vaginal dryness, without disrupting the efficacy of endocrine therapies. This is mainly because it primarily rectifies hormone imbalances rather than targeting cancer cells, guaranteeing a better quality of life for patients undergoing cancer treatment. As an illustration, NHS England, a government agency based in the UK, reported that during 2022-23, there were 11 million prescriptions for hormone replacement therapy (HRT), which is a 47% rise from 2021-22 in England. Consequently, the surge in hormone replacement therapy (HRT) propels the metastatic HR+/HER2− breast cancer market.
How Is the Metastatic HR+/HER2- Breast Cancer Market Segmented?
The metastatic hr+/her2− breast cancermarket covered in this report is segmented –
1) By Drugs: Paclitaxel; Tamoxifen; Vinblastine; Raloxifene; Docetaxel; Other Drugs
2) By Treatment: Radiation Therapy; Vitamin Therapy; Macrobiotic Diets; Homeopathy; Herbal Medication
3) By End-User: Hospitals; Clinics; Other End-User
Subsegments:
1) By Paclitaxel: Generic Paclitaxel; Taxol
2) By Tamoxifen: Generic Tamoxifen; Nolvadex
3) By Vinblastine: Generic Vinblastine; Velban
4) By Raloxifene: Generic Raloxifene; Evista
5) By Docetaxel: Generic Docetaxel; Taxotere
6) By Other Drugs: Letrozole; Anastrozole; Exemestane; Palbociclib; Ribociclib; Abemaciclib
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21220&type=smp
Which Regions Are Driving the Next Phase of the Metastatic HR+/HER2- Breast Cancer Market Growth?
North America was the largest region in the dominated market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic HR+/HER2− breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Metastatic HR+/HER2- Breast Cancer Market?
Leading firms in the metastatic HR+/HER2- breast cancer market are innovating through combination therapy developments in order to broaden their market presence and treatment offerings. Combining two or more therapeutic agents, such as chemotherapy, targeted therapy, immunotherapy or hormone therapy, is a treatment strategy aimed at effectively managing a medical condition by gaining more comprehensive treatment results and minimizing the chance of resistance development to a singular treatment methodology. For example, July 2023 saw Merck & Co., Inc., an American pharmaceutical entity, publicize the Phase 3 KEYNOTE-756 trial for KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, in conjunction with chemotherapy approved by the Food and Drug Administration, a regulatory body within the United States. The trial, by reaching its main objective, significantly advanced the pathological complete response (pCR) rate amongst patients with high-risk, early-stage ER+/HER2- breast cancer. Pioneering in its approach, the KEYNOTE-756 trial is the first Phase 3 trial that evidenced a meaningful improvement in pCR rate through an immunotherapy regime in the neoadjuvant scenario for patients. The trial explored the use of KEYTRUDA paired with chemotherapy as a neoadjuvant treatment, followed by supplementary KEYTRUDA and endocrine therapy, for early-stage, high-risk ER+/HER2- breast cancer.
View the full report here:
How Is the Metastatic HR+/HER2- Breast Cancer Market Defined and What Are Its Core Parameters?
Metastatic HR+/HER2− breast cancer refers to a form of breast cancer where the cancer cells have spread beyond the breast to other parts of the body. Metastatic HR+/HER2− breast cancer is treated using targeted therapies, hormonal treatments, and chemotherapy to manage disease progression and improve patient outcomes.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21220
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model